Unravelling subjectivity, embodied experience and (taking) psychotropic medication.
Feminist science studies
Intra-action
Mental health
Psychiatry
Psychotropic medication
Subjectivity
Journal
Social science & medicine (1982)
ISSN: 1873-5347
Titre abrégé: Soc Sci Med
Pays: England
ID NLM: 8303205
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
17
12
2018
revised:
31
03
2019
accepted:
02
04
2019
pubmed:
13
4
2019
medline:
7
7
2020
entrez:
13
4
2019
Statut:
ppublish
Résumé
This paper explores how distinctions between 'intended' and 'side' effects are troubled in personal narratives of taking psychotropic medications. Grounded in interviews with 29 participants diagnosed with mental illness in Victoria, Australia between February and December 2014, we consider how people interpret pharmaceutical compounds beyond their desired or intended effects, and how such effects shape and transform subjectivity and their relationship with their bodies. This paper contributes to recent discussions of mental illness and medication effects, informed by feminist science studies. It emphasises the co-constitution of social, affective and material relations in the context of 'taking' psychotropic medication. This paper discusses three key themes as important to the phenomenology of the nexus of illness and psychotropic medication: movement, ambivalence, and sociality. Our analysis demonstrates how psychotropic drugs are productive of subjectivity through their promises and potential, their unexpected harms and the institutions from which they are inseparable.
Identifiants
pubmed: 30978572
pii: S0277-9536(19)30198-4
doi: 10.1016/j.socscimed.2019.04.004
pmc: PMC6529876
pii:
doi:
Substances chimiques
Psychotropic Drugs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-73Subventions
Organisme : Wellcome Trust
ID : 209513/Z/17/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.
Références
Lancet. 2007 Feb 24;369(9562):700-2
pubmed: 17321317
Int J Drug Policy. 2013 May;24(3):167-72
pubmed: 23352332
Issues Ment Health Nurs. 2004 Dec;25(8):783-98
pubmed: 15545243
Psychol Psychother. 2004 Mar;77(Pt 1):19-33
pubmed: 15025902
Soc Sci Med. 2016 Aug;163:98-106
pubmed: 27423066
Soc Sci Med. 2007 Aug;65(4):698-711
pubmed: 17507129
Soc Sci Med. 2015 Aug;138:44-56
pubmed: 26046726
Aust N Z J Ment Health Nurs. 2001 Sep;10(3):145-55
pubmed: 11493286
Qual Res Psychol. 2013 Jul;10(3):318-339
pubmed: 23606810
Soc Sci Med. 2006 Jun;62(11):2861-73
pubmed: 16343722
Qual Health Res. 2018 May;28(6):1002-1015
pubmed: 29557294
Soc Sci Med. 1998 Nov;47(9):1313-23
pubmed: 9783874
Clin Neuropharmacol. 2011 Nov-Dec;34(6):248-55
pubmed: 21996646
Soc Sci Med. 2009 May;68(10):1882-91
pubmed: 19342139
Drug Saf. 2000 Jan;22(1):73-81
pubmed: 10647977
Int J Ment Health Nurs. 2015 Jun;24(3):253-61
pubmed: 25529392
Compr Psychiatry. 2003 Mar-Apr;44(2):121-34
pubmed: 12658621
Soc Sci Med. 2015 Oct;143:311-9
pubmed: 25779773
Cult Med Psychiatry. 2012 Mar;36(1):26-50
pubmed: 22246852
J Psychiatr Res. 2003 May-Jun;37(3):193-220
pubmed: 12650740
Compr Psychiatry. 1975 Jan-Feb;16(1):43-7
pubmed: 234073
J Psychopharmacol. 2008 May;22(3):238-43
pubmed: 18541624
Eur Psychiatry. 2004 Nov;19(7):415-22
pubmed: 15504648